Skip to main content
. 2024 Jul 2;12(7):734. doi: 10.3390/vaccines12070734

Figure 2.

Figure 2

Percentages (95% CIs) of participants achieving seroresponses to Omicron XBB.1.5 (a), BA.2.86 (b), and JN.1 (c) 1 month after vaccination with monovalent XBB.1.5-adapted or bivalent BA.4/BA.5-adapted BNT162b2 30 μg. The definition of seroresponse was at least a 4-fold rise from before to 1 month after study vaccination in the SARS-CoV-2 FFRNT 50% serum neutralizing titers. For participants with a baseline measurement <LLOQ, seroresponse was defined as a postvaccination assay result of ≥4 × LLOQ. FFRNT = fluorescent focus reduction neutralization test; LLOQ = lower limit of quantitation.